RESULTS OF A PHASE 1 CLINICAL TRIAL (GH001-HV- 103) TO DETERMINE THE SAFETY AND TOLERABILITY OF MEBUFOTENIN (5-MEO- DMT), ADMINISTERED VIA INHALATION (GH001) IN HEALTHY SUBJECTS

Authors
Category Primary study
ConferenceASCPT 2025 Annual Meeting
Year 2025
This article has no abstract
Epistemonikos ID: 80f0533d0cfb56b57a5145016e0ac9569ffefa3c
First added on: Feb 21, 2026